US

Mindset Ventures targets $25 mln for sophomore fund

Brazil-based Mindset Ventures is seeking to raise around $25 million for its second fund. The fund will focus on investing between $200,000 and $1 million apiece in startups in the U.S. and Israel.

IoT platform Seebo locks in $8 mln

Tel Aviv, Israel-based Seebo, an internet of things platform, has raised an additional $8 million to its Series A funding round, adding the total tally to $16.5 million. The investors include Pritzker Group Venture Capital, TPY Capital, Viola Ventures and Global IoT Technology Ventures.

Empiric Health lands $3 mln

Healthcare startup Empiric Health, has secured $3 million in financing. The investor was Intermountain Healthcare.

ElectroCore hauls in over $70 mln

Basking Ridge, New Jersey-based ElectroCore, a bioelectronic medicine healthcare company, has closed over $70 million in Series B financing. Core Ventures led the round.

Codiak BioSciences nets $76.5 mln Series C

Codiak BioSciences Inc, an exosome therapeutics company, has secured $76.5 million in Series C financing. Codiak's investors include ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, Alexandria Venture Investments, Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital and Casdin Capital.

Medical apparel brand Jaanuu pulls in funding

Medical apparel brand Jaanuu has secured an undisclosed amount of funding. The investors included Dan Nordstrom, former co-president of Nordstrom and his Nordstrom family, Georg Richter, former president and COO of Guthy-Renker, Innovation Global Capital and Maywic Select Investments.

Apexian Pharmaceuticals grabs Series A

Apexian Pharmaceuticals, an Indiana-based clinical stage biotechnology company, has raised an undisclosed amount of Series A funding. Apexian's investors included Elevate Ventures.

VC-backed TM3 Therapeutics appoints board chairman

TM3 Therapeutics, a developer of treatments for rare neurodegenerative and metabolic disorders, has named Dr. Peter Van Vlasselaer as chairman of its board of directors. Currently, he is the CEO of ARMO Biosciences. TM3's backers include Sofinnova Partners and INKEF Capital.

Sofinnova Partners recruits Bhaman as partner

Sofinnova Partners, a European life sciences venture firm, has appointed Maina Bhaman as a partner. Previously, she worked at Touchstone Innovations where she was director of healthcare investment.

Y-mAbs Therapeutics rakes in $30 mln

Y-mAbs Therapeutics Inc, a New York City and Denmark-based developer of cancer treatments, has raised $30 million in a private placement. The investors were Sofinnova Ventures and Scopia Capital Management.